Targeted Cures: A Policy Discussion on Treating Patients with Rare Diseases
![Targeted Cures: A Policy Discussion on Treating Patients with Rare Diseases](https://i0.wp.com/digital-stage.thehill.com/wp-content/uploads/sites/2/2016/06/targeted-cures-a-policy-discussion-on-treating-patients-with-rare-diseases.jpg?w=2000&ssl=1)
On Wednesday, May 11, The Hill convened a discussion on delivering innovative new treatments to rare disease patients. Topics of discussion included: public-private partnerships to develop treatments and bring them to market, the cutting-edge science and medicine driving rare disease advances, and the path to making care accessible to the patients who need it most.
Featured speakers included:
SENATOR BOB CASEY (D-PA)
CONGRESSMAN FRED UPTON (R-MI-6), Chairman, House Committee on Energy & Commerce
CHRISTOPHER P. AUSTIN, M.D., Director, National Center for Advancing Translational Sciences, National Institutes of Health
LORRI KNOX CAREY, ALS Advocate
PETER PITTS, President & Co-Founder, Center for Medicine in the Public Interest
DR. GEORGE A. SCANGOS, CEO, Biogen
STEPHEN J. UBL, President & CEO, PhRMA
Sponsored by: